Nav: Home

When green means stop

March 22, 2017

Optogenetics, the approach to use light to control key processes, has revolutionized how researchers investigate cellular signaling pathways, cellular behavior and the function of large and interconnected tissues such as the brain. This highly successful combination of optics and genetics is powered by light-sensitive proteins, many of which have been engineered to bind to each other upon light stimulation. New research by scientists at the Institute of Science and Technology Austria (IST Austria) expands this optogenetic protein toolbox. In the study by the group of Harald Janovjak, driven by first author and PhD student Stephanie Kainrath, and colleagues at the Children's Cancer Research Institute in Vienna, published today in Angewandte Chemie, the authors demonstrate the release of binding when exposed to green light.

The application of light as a stimulus has allowed researchers to manipulate cellular behavior in defined spaces and real-time and thereby opened doors for new types of experiments. The method has, however, flourished in those cases where light-sensitive protein parts, called protein domains, responded to light by binding to each other. Binding activates signaling. To ensure that signaling remains turned on, the cells, tissues or animals under study need to stay in the light. But constant exposure to light carries risks: bleaching and toxic side effects of light are commonly observed.

Kainrath and colleagues offer a way out as they re-purposed light-sensitive domains that release their interaction in response to light. As a consequence, researchers can now leave their study object in the dark to induce signaling, and move it into light at a precise timepoint to interrupt signaling. First author Stephanie Kainrath explains the significance of the research: "Our work was inspired by the desire to imitate biological signals that are always on, such as those that drive the growth of certain cancers. With our new tool we can also rapidly switch off such signals. This allows for new approaches in both cell-based and animal studies."

The newly engineered tool is especially versatile as it responds to light in the green part of the visible light spectrum. This is possible as the re-purposed domains, called cobalamin (vitamin B12)-binding domains (CBDs), utilize Vitamin B12 for their light response. It was only recently realized that Vitamin B12 is not only essential for human body function but also used in bacteria as a light sensor. Kainrath and colleagues demonstrate the use of these domains by linking them to a vertebrate receptor protein called fibroblast growth factor receptor 1 (FGFR1). Normally a part of these receptor reaches to the outside of cell where it can capture fibroblast growth factors, causing two receptors to bind to each other and activate signaling on the inside of the cell. The engineered optogenetic FGFR1 proteins bind to each other in the dark via the CBDs and activate signaling. Only in green light, the binding is released and signaling stops.

Experiments in zebrafish embryos showcase the potential of this new approach for animal studies. Zebrafish embryos modified to produce the engineered receptor and kept in the dark show the same developmental defects as embryos in which signaling is always active, a situation that resembles human disorders. By contrast, embryos that were allowed to develop in green light were normal, without any developmental defects. For Martin Distel, co-author and group leader at the Children's Cancer Research Institute, Vienna, the receptor is a useful tool for addressing oncogene addiction, the Achilles heel of some cancers: "CBD mediated and green light-controlled dissociation of protein complexes is a useful asset in the optogenetic toolbox. For potential applications in cancer research one might think of oncogene addiction. Aberrant activation of signals such as those linked to FGFs can now be shut down rapidly and from the outside by light to investigate consequences on cell behavior."

Harald Janovjak and his group work in the new field of synthetic physiology, which tackles complex biological problems with the approach to "build it to understand it". Stephanie Kainrath joined IST Austria's PhD program in 2015. Having passed her qualifying exam in December 2016, Stephanie now pursues research for her doctoral degree in the group of Harald Janovjak.

Institute of Science and Technology Austria

Related Cancer Research Articles:

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.
Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.
Cancer Research UK boosts efforts to overcome deadliest cancer as rates climb
CANCER RESEARCH UK has tripled its investment in pancreatic cancer, one of the hardest cancers to treat, since launching its research strategy in 2014 according to new figures published today (Wednesday).
Children's Research Institute at UT Southwestern research garners Stand Up To Cancer grant
Dr. Hao Zhu, Assistant Professor of Children's Medical Center Research Institute at UT Southwestern, is one of 10 researchers in the nation to receive a Stand Up to Cancer grant to further his studies of a gene whose absence protects mice against liver cancer and promotes liver tissue regeneration in mammals.
NYU's Perlmutter Cancer Center & the Technion launch global cancer research initiative
Drug-carrying 'nanoghosts' that battle melanoma and new treatments for malignant mesothelioma will be the focus of the first joint research projects led by NYU Langone Medical Center and the Technion-Israel Institute of Technology.
Ludwig Cancer Research and CRI initiate clinical trial of immunotherapy for ovarian cancer
Ludwig Cancer Research and the Cancer Research Institute (CRI) have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
Cancer research at Marshall University shows promise for combating deadly lung cancer
A study by researchers at Marshall University Joan C. Edwards School of Medicine has found that blocking the blood supply of small cell lung cancer tumors may help reduce their growth and delay the regrowth process after treatment.

Related Cancer Research Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...